Interim report January – March 2022
The period in summary First quarter January 1 – March 31, 2022 – On March 23 the first batch of Strangvac was released for sale in Sweden. – Intervacc has applied for supplementary protection certificates (SPCs) for Strangvac in key European markets. SPCs are an intellectual property right that serves as an extension to a patent right. – EMA extended the shelf life of the antigens used in Strangvac to 28 months. – During February an application for a Permit for Sale and Distribution of Strangvac in the U.S. was submitted to the U.S. Department of